Astria Therapeutics Inc ATXS

$12.58 +0.08 (0.64%)

Valuation

Market cap: 718,129,000
Revenue TTM: $0
Net income TTM: $-94,260,000
PE ratio: 0.00
Forward PE: —
Profit margin: 0.00%
Debt to equity: 0.00

Trading

Volume: 3,199,300
Avg volume: 1,103,906
Day's range: $12.45 – $12.59
Shares out: 57,085,000
Stochastic %K: 33%
Beta: 0.01
Analysts: Sell
Price target: $20.00

Price

Company profile

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. As of January 23, 2026, Astria Therapeutics, Inc. operates as a subsidiary of BioCryst Pharmaceuticals, Inc.

Industry: Biotechnology
Sector: Healthcare
Phone: 617 349 1971
Website: https://www.astriatx.com
Address: 22 Boston Wharf Road, 10th floor, Boston, United States

Latest news

No headlines yet.

Stocktwits

Rayvio_News_Filter Oct 26, 12:02 PM

$ATXS 🏥 Novastra Therapeutics Inc. reported encouraging initial data from an ongoing investigator-initiated Phase 1 study of its XIRT/OAP cancer immune therapy, providing first clinical evidence for the platform. Curated for market relevance More market highlights: https://rayvio.app/dashboard/?utm_source=lifatpt

0 replies

MarketScoutTrades Jun 28, 10:14 PM

$ATXS is basically gone from the tape now after getting absorbed into $BCRX in that Jan 2026 deal. This isn’t a trading setup anymore, it’s just legacy flow getting folded into a larger biotech story. What used to be a standalone HAE pipeline name (STAR programs, early-stage optionality) is now just part of BioCryst’s balance sheet and execution risk. Anyone still talking $ATXS like it’s a live ticker is basically replaying old data.

0 replies

NVDAMillionaire Feb 4, 4:53 PM

$ATXS Brilliant piece that captures ATXS's situation perfectly. So if you want to update your understanding of ATXS or get to know ATXS better, this is essential reading. https://everyticker.com/quote/ATXS/analysis/astria-therapeutics-unlocking-value-through-a-differentiated-dual-asset-pipeline-nasdaq-atxs

0 replies

G101SPM Jan 23, 2:23 PM

$BCRX $6.74 Holding long position https://stocktwits.com/search/u/G101SPM?symbol=BCRX BRIEF: BioCryst Pharma completes acquisition of Astria Therapeutics ($ATXS) The transaction strengthens its position as a leader in hereditary angioedema and enhances the company's long-term growth trajectory. BioCryst adds navenibart, a late-stage, long-acting plasma kallikrein inhibitor currently in Phase 3 clinical development, to its HAE portfolio. The potential to be the first HAE therapy with every-three and every-six month dosing, combined with a high level of attack control, positions navenibart to significantly improve the treatment experience for HAE patients. BioCryst also obtains Astria's early-stage program for atopic dermatitis, STAR0310, for which the company plans to pursue strategic alternatives. The acquisition was completed for an implied transaction value of approximately $700 million.

0 replies

G101SPM Jan 22, 11:17 AM

$ATXS $12.50 bid Holding long position at $7.60 (net cost) https://stocktwits.com/G101SPM/message/602342237 BRIEF: Astria Therapeutics stockholders vote to approve acquisition by BioCryst ($BCRX); parties expect the Merger to close on or about January 23. 2026. note: Carrying long position of BCRX.

0 replies

ShortsHater Jan 21, 9:31 PM

$BCRX and $ATXS merger done, better days ahead

0 replies

Mergerbrief Jan 21, 1:09 PM

$ATXS / $BCRX – Shareholder Vote $ATXS MergerBrief.com M&A Tracking

0 replies

Night_Owl_Biotech Jan 19, 6:58 PM

Attached is a compilation of $BCRX & $ATXS operating forecasts as prepared by ATXS management. ATXS management projected BCRX revenues would peak in FY2030. ATXS projects 95% gross margins on Navenibart sales. At the bottom is a comparison of BCRX analyst estimates versus the total revenues forecast by ATXS management. This is for informational purposes only. This is not investment advice. $XBI $IBB $NBI

2 replies